Lauren C Harshman1, Victoria X Wang2, Anis A Hamid1, Gabriella Santone3, Charles G Drake4, Michael A Carducci5, Robert S DiPaola6, Raina N Fichorova3, Christopher J Sweeney1. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Harvard Medical School, Boston, Massachusetts, USA. 2. Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 3. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. 4. Department of Medicine, Division of Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA. 5. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA. 6. Department of Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Abstract
BACKGROUND: The immunosuppressive cytokine interleukin- 8 (IL-8), produced by tumor cells and some myeloid cells, promotes inflammation, angiogenesis, and metastasis. In our discovery work, elevated serum IL-8 at androgen deprivation therapy (ADT) initiation portended worse overall survival (OS). Leveraging serum samples from the phase 3 CHAARTED trial of patients treated with ADT +/- docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC), we validated these findings. METHODS: Two hundred and thirty-three patients had serum samples drawn within 28 days of ADT initiation. The samples were assayed using the same Mesoscale Multiplex ELISA platform employed in the discovery cohort. After adjusting for performance status, disease volume, and de novo/metachronous metastases, multivariable Cox proportional hazards models assessed associations between IL-8 as continuous and binary variables on OS and time to castration-resistant prostate cancer (CRPC). The median IL-8 level (9.3 pg/ml) was the a priori binary cutpoint. Fixed-effects meta-analyses of the discovery and validation sets were performed. RESULTS: Higher IL-8 levels were prognostic for shorter OS (continuous: hazard ratio [HR] 2.2, 95% confidence interval [CI]: 1.4-3.6, p = .001; binary >9.3: HR 1.7, 95% CI: 1.2-2.4, p = .007) and time to CRPC (continuous: HR 2.3, 95% CI: 1.6-3.3, p < .001; binary: HR 1.8, 95% CI: 1.3-2.5, p < .001) and independent of docetaxel use, disease burden, and time of metastases. Meta-analysis including the discovery cohort, also showed that binary IL-8 levels >9.3 pg/ml from patients treated with ADT alone was prognostic for poorer OS (HR 1.8, 95% CI: 1.2-2.7, p = .007) and shorter time to CRPC (HR 1.4, 95% CI: 0.99-1.9, p = .057). CONCLUSIONS: In the phase 3 CHAARTED study of men with mHSPC at ADT initiation, elevated IL-8 portended worse survival and shorter time to castration-resistant prostate cancer independent of docetaxel administration, metastatic burden, and metachronous versus de novo metastatic presentation. These findings support targeting IL-8 as a strategy to improve mHSPC outcomes.
BACKGROUND: The immunosuppressive cytokine interleukin- 8 (IL-8), produced by tumor cells and some myeloid cells, promotes inflammation, angiogenesis, and metastasis. In our discovery work, elevated serum IL-8 at androgen deprivation therapy (ADT) initiation portended worse overall survival (OS). Leveraging serum samples from the phase 3 CHAARTED trial of patients treated with ADT +/- docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC), we validated these findings. METHODS: Two hundred and thirty-three patients had serum samples drawn within 28 days of ADT initiation. The samples were assayed using the same Mesoscale Multiplex ELISA platform employed in the discovery cohort. After adjusting for performance status, disease volume, and de novo/metachronous metastases, multivariable Cox proportional hazards models assessed associations between IL-8 as continuous and binary variables on OS and time to castration-resistant prostate cancer (CRPC). The median IL-8 level (9.3 pg/ml) was the a priori binary cutpoint. Fixed-effects meta-analyses of the discovery and validation sets were performed. RESULTS: Higher IL-8 levels were prognostic for shorter OS (continuous: hazard ratio [HR] 2.2, 95% confidence interval [CI]: 1.4-3.6, p = .001; binary >9.3: HR 1.7, 95% CI: 1.2-2.4, p = .007) and time to CRPC (continuous: HR 2.3, 95% CI: 1.6-3.3, p < .001; binary: HR 1.8, 95% CI: 1.3-2.5, p < .001) and independent of docetaxel use, disease burden, and time of metastases. Meta-analysis including the discovery cohort, also showed that binary IL-8 levels >9.3 pg/ml from patients treated with ADT alone was prognostic for poorer OS (HR 1.8, 95% CI: 1.2-2.7, p = .007) and shorter time to CRPC (HR 1.4, 95% CI: 0.99-1.9, p = .057). CONCLUSIONS: In the phase 3 CHAARTED study of men with mHSPC at ADT initiation, elevated IL-8 portended worse survival and shorter time to castration-resistant prostate cancer independent of docetaxel administration, metastatic burden, and metachronous versus de novo metastatic presentation. These findings support targeting IL-8 as a strategy to improve mHSPC outcomes.
Authors: Nrupen A Bhavsar; Jay H Bream; Alan K Meeker; Charles G Drake; Sarah B Peskoe; Djeneba Dabitao; Angelo M De Marzo; William B Isaacs; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-22 Impact factor: 4.254
Authors: Mei-Yin C Polley; Boris Freidlin; Edward L Korn; Barbara A Conley; Jeffrey S Abrams; Lisa M McShane Journal: J Natl Cancer Inst Date: 2013-10-17 Impact factor: 13.506
Authors: Ravikumar Aalinkeel; Bindukumar Nair; Chih-Kuang Chen; Supriya D Mahajan; Jessica L Reynolds; Hanguang Zhang; Haotian Sun; Donald E Sykes; Kailash C Chadha; Steven G Turowski; Katelyn D Bothwell; Mukund Seshadri; Chong Cheng; Stanley A Schwartz Journal: Immunology Date: 2016-08 Impact factor: 7.397
Authors: Catherine Murphy; Maryalice McGurk; Johanna Pettigrew; Alfredo Santinelli; Roberta Mazzucchelli; Patrick G Johnston; Rodolfo Montironi; David J J Waugh Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson Journal: Nat Rev Cancer Date: 2007-04 Impact factor: 60.716
Authors: Shinako Araki; Yohei Omori; Dominic Lyn; Rajendra K Singh; David M Meinbach; Yekutiel Sandman; Vinata B Lokeshwar; Bal L Lokeshwar Journal: Cancer Res Date: 2007-07-15 Impact factor: 12.701
Authors: A R Hansen; C Massard; P A Ott; N B Haas; J S Lopez; S Ejadi; J M Wallmark; B Keam; J-P Delord; R Aggarwal; M Gould; P Yang; S M Keefe; S A Piha-Paul Journal: Ann Oncol Date: 2018-08-01 Impact factor: 32.976
Authors: M F Sanmamed; J L Perez-Gracia; K A Schalper; J P Fusco; A Gonzalez; M E Rodriguez-Ruiz; C Oñate; G Perez; C Alfaro; S Martín-Algarra; M P Andueza; A Gurpide; M Morgado; J Wang; A Bacchiocchi; R Halaban; H Kluger; L Chen; M Sznol; I Melero Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Marijo Bilusic; Christopher R Heery; Julie M Collins; Renee N Donahue; Claudia Palena; Ravi A Madan; Fatima Karzai; Jennifer L Marté; Julius Strauss; Margaret E Gatti-Mays; Jeffrey Schlom; James L Gulley Journal: J Immunother Cancer Date: 2019-09-05 Impact factor: 13.751
Authors: Eshwari Dathathri; Khrystany T Isebia; Fikri Abali; Martijn P Lolkema; John W M Martens; Leon W M M Terstappen; Ruchi Bansal Journal: Front Oncol Date: 2022-05-20 Impact factor: 5.738